Methods of reducing apolipoprotein C-III
View Patent ↗In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
1. A method of reducing an apolipoprotein C-III level of a subject having fasting baseline triglycerides of at least about 500 mg/dl, the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day, wherein the apolipoprotein C-III level is reduced by at least about 5%.
2. The method of claim 1 , wherein the apolipoprotein C-III level is reduced by at least about 25%.
3. The method of claim 1 , wherein about 2 g per day of ethyl eicosapentaenoate is administered to the subject.
4. The method of claim 1 , wherein about 3.8 g to about 4 g per day of ethyl eicosapentaenoate is administered to the subject.
5. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject daily for a period of 1 to about 12 weeks.
6. The method of claim 1 , wherein the reduction in APOC3 level is in comparison to control subjects having fasting triglycerides of at least about 500 mg/dl who have not received the pharmaceutical composition.
7. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95%, by weight of all fatty acids present, ethyl eicosapentaenoate.
8. The method of claim 1 , wherein the pharmaceutical composition comprises no more than about 10%, by weight of all fatty acids present, docosahexaenoic acid or a derivative thereof, if any.
9. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95%, by weight of all fatty acids present, ethyl eicosapentaenoate and no more than about 2%, by weight of all fatty acids present, docosahexaenoic acid or a derivative thereof, if any.